{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Intrahepatic+Cholangiocarcinoma&page=2", "query": { "condition": "Unresectable Intrahepatic Cholangiocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Intrahepatic+Cholangiocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T08:49:30.962Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04491942", "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Bile Duct Carcinoma", "Advanced Breast Carcinoma", "Advanced Cervical Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Esophageal Carcinoma", "Advanced Gastric Carcinoma", "Advanced Head and Neck Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Ovarian Carcinoma", "Advanced Penile Carcinoma", "Advanced Pleural Malignant Mesothelioma", "Advanced Urothelial Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Distal Bile Duct Cancer AJCC v8", "Stage III Intrahepatic Bile Duct Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Penile Cancer AJCC v8", "Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Intrahepatic Bile Duct Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2021-08-25", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 7, "location_summary": "Sacramento, California • Bethesda, Maryland • New York, New York + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04491942" }, { "nct_id": "NCT04941287", "title": "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Distal Bile Duct Adenocarcinoma", "Metastatic Gallbladder Carcinoma", "Metastatic Intrahepatic Cholangiocarcinoma", "Recurrent Distal Bile Duct Adenocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Liver Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Varlilumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2021-12-15", "completion_date": "2026-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04941287" }, { "nct_id": "NCT00553332", "title": "Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver and Intrahepatic Biliary Tract Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Unresectable Extrahepatic Bile Duct Cancer" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-11", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2016-04-22", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 7, "location_summary": "Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00553332" }, { "nct_id": "NCT05564403", "title": "Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Gallbladder Carcinoma", "Advanced Intrahepatic Cholangiocarcinoma", "Recurrent Biliary Tract Carcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Stage III Distal Bile Duct Cancer AJCC v8", "Stage III Gallbladder Cancer AJCC v8", "Stage III Hilar Cholangiocarcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Hilar Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Biliary Tract Carcinoma", "Unresectable Gallbladder Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-02-09", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 208, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 163 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564403" }, { "nct_id": "NCT06160752", "title": "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Cholangiocarcinoma", "Intrahepatic Cholangiocarcinoma", "Solid Tumor", "Metastatic Cholangiocarcinoma" ], "interventions": [ { "name": "Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" }, { "name": "Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-11-22", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160752" }, { "nct_id": "NCT00005938", "title": "DX-8951f in Treating Patients With Biliary Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer" ], "interventions": [ { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 5, "location_summary": "Denver, Colorado • New York, New York • Dallas, Texas + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005938" }, { "nct_id": "NCT02856568", "title": "Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Resectable Cholangiocarcinoma", "Recurrent Cholangiocarcinoma", "Stage III Extrahepatic Bile Duct Cancer", "Stage III Intrahepatic Cholangiocarcinoma", "Stage IIIA Hilar Cholangiocarcinoma", "Stage IIIB Hilar Cholangiocarcinoma", "Stage IVA Extrahepatic Bile Duct Cancer", "Stage IVA Hilar Cholangiocarcinoma", "Stage IVA Intrahepatic Cholangiocarcinoma", "Stage IVB Extrahepatic Bile Duct Cancer", "Stage IVB Hilar Cholangiocarcinoma", "Stage IVB Intrahepatic Cholangiocarcinoma", "Unresectable Extrahepatic Bile Duct Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ricolinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-05-01", "completion_date": "2021-10", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02856568" }, { "nct_id": "NCT04301778", "title": "Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "SNDX-6352", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-08-24", "completion_date": "2024-02-06", "has_results": true, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04301778" }, { "nct_id": "NCT04251715", "title": "mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver and Intrahepatic Bile Duct Carcinoma", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Implanted Medical Device", "type": "DEVICE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-04-28", "completion_date": "2025-11-30", "has_results": false, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04251715" }, { "nct_id": "NCT04175912", "title": "Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cholangiocarcinoma", "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Cholangiocarcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-03-16", "completion_date": "2026-10-31", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-22T08:49:30.962Z", "location_count": 420, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04175912" } ] }